Tvardi Therapeutics (NASDAQ:TVRD) Releases Quarterly Earnings Results, Misses Expectations By $0.49 EPS

Key Points

• Tvardi Therapeutics reported a quarterly EPS of ($1.00), missing estimates by ($0.49).
• The company has a negative net margin of 595.39% and return on equity of 710.04%, indicating significant financial challenges.
• Tvardi's stock has a twelve-month range of $8.13 to $34.31, with analysts giving it a consensus rating of "Moderate Buy" and an average target price of $64.25.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.49), Zacks reports. Tvardi Therapeutics had a negative return on equity of 710.04% and a negative net margin of 595.39%.

Tvardi Therapeutics Stock Performance

NASDAQ TVRD traded down $0.14 during trading hours on Tuesday, hitting $24.60. The company's stock had a trading volume of 6,362 shares, compared to its average volume of 33,509. Tvardi Therapeutics has a 52 week low of $8.13 and a 52 week high of $34.31. The company's 50-day moving average price is $24.91.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Tvardi Therapeutics in a research report on Friday, July 11th. They set an "overweight" rating and a $52.00 price objective on the stock. Oppenheimer assumed coverage on shares of Tvardi Therapeutics in a research report on Wednesday, May 21st. They set an "outperform" rating and a $65.00 price objective on the stock. Piper Sandler assumed coverage on shares of Tvardi Therapeutics in a research report on Thursday, June 12th. They set an "overweight" rating and a $78.00 price objective on the stock. Wall Street Zen raised shares of Tvardi Therapeutics to a "hold" rating in a research report on Saturday, May 24th. Finally, Raymond James Financial assumed coverage on shares of Tvardi Therapeutics in a research report on Monday, July 14th. They set an "outperform" rating and a $62.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Tvardi Therapeutics has an average rating of "Buy" and a consensus target price of $64.25.

Hedge Funds Weigh In On Tvardi Therapeutics

Several hedge funds have recently modified their holdings of TVRD. Geode Capital Management LLC bought a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $2,617,000. Marshall Wace LLP bought a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $583,000. Bank of America Corp DE bought a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $399,000. New York State Common Retirement Fund bought a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $92,000. Finally, Headlands Technologies LLC bought a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $80,000. Institutional investors own 44.66% of the company's stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.